Evidence map›Paper›PMID 41784336›Full record

Observational studyInvestigative ophthalmology & visual science2026

Hyperspectral Imaging for the Classification and Analysis of Drusen in Age-Related Macular Degeneration.

Chong Chen, Raha Razavi, Francesco Romano, Heiko Niessen, Samin Sabokrohiyeh, Anudeep Konda, Claudia Chevrefils, Jean Daniel Arbour, Marc-André Rhéaume, Ramina Nissan and 10 more

Abstract readObservational Study
In one paragraph

Observational study in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Chong ChenHarvard Retinal Imaging Lab, Harvard Medical School, Boston, Massachusetts, United States.
Raha RazaviBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
Francesco RomanoHarvard Retinal Imaging Lab, Harvard Medical School, Boston, Massachusetts, United States.
Heiko NiessenBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
Samin SabokrohiyehOptina Diagnostics, Montréal, Québec, Canada.
Anudeep KondaOptina Diagnostics, Montréal, Québec, Canada.
Claudia ChevrefilsOptina Diagnostics, Montréal, Québec, Canada.
Jean Daniel ArbourClinique Ophtalmologique 2121, Montréal, Québec, Canada.
Marc-André RhéaumeClinique Ophtalmologique 2121, Montréal, Québec, Canada.
Ramina NissanOptina Diagnostics, Montréal, Québec, Canada.
Anthéa RojewskiOptina Diagnostics, Montréal, Québec, Canada.
Patricia SoryaOptina Diagnostics, Montréal, Québec, Canada.
Lara SantucciOptina Diagnostics, Montréal, Québec, Canada.
Shannon CampbellOptina Diagnostics, Montréal, Québec, Canada.
Ioanna PloumiHarvard Retinal Imaging Lab, Harvard Medical School, Boston, Massachusetts, United States.
Ying ZhuHarvard Retinal Imaging Lab, Harvard Medical School, Boston, Massachusetts, United States.
Xinyi DingHarvard Retinal Imaging Lab, Harvard Medical School, Boston, Massachusetts, United States.
Jean-Philippe SylvestreOptina Diagnostics, Montréal, Québec, Canada.
John B MillerHarvard Retinal Imaging Lab, Harvard Medical School, Boston, Massachusetts, United States.
Khaled NassarBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To characterize the spatial-spectral signatures of drusenoid deposits [soft, hard, and reticular pseudodrusen (RPD)] in eyes with non-exudative age-related macular degeneration (AMD). Methods: In this observational, cross-sectional, prospective study, hyperspectral retinal images and corresponding Optical Coherence Tomography (OCT) images were collected from 152 eyes of 100 participants with non-exudative AMD. Drusenoid deposits were manually annotated in 148 eyes (97 participants) by retinal specialists using OCT as the reference standard. Automated drusen identification was then performed using spectral angle mapper (SAM) and random forest classifiers. Results: Hyperspectral imaging revealed that RPD was most distinct at 470-500 nm, soft drusen at 525-575 nm, hard drusen at 620-675 nm, and pigmentary abnormalities at 650-725 nm. Using the SAM classifier, drusenoid deposits were identified with 97% sensitivity and 70% specificity. The random forest classifier achieved higher overall performance, with 88% sensitivity, 99% specificity, and an area under the receiver operating characteristic curve of 0.96. Pixel-wise SAM mapping delineated drusenoid deposits and healthy retina, extending beyond annotated regions. Conclusions: Distinct spatial-spectral signatures for soft drusen, hard drusen, and RPD were identified using hyperspectral imaging. Both SAM and random forest classifiers demonstrated promising results for automated drusenoid deposit detection. These findings support the role of hyperspectral retinal imaging as a noninvasive tool for automated drusen mapping and patient risk stratification in nonexudative AMD.

Indexed as

Hyperspectral ImagingMacular DegenerationRetinal DrusenTomography, Optical CoherenceAgedAged, 80 and overCross-Sectional StudiesFemaleHumansMaleProspective StudiesROC CurveSensitivity and Specificity

Identifiers

PMID41784336
PMCPMC12967124

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.